SCHEMBL7666089

SCHEMBL7666089

CCCCOC(=O)NCCc1cc[c]cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 14/20 0.54
KMT2A Q03164 2/20 0.52
GLA P06280 1/20 0.52
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5110887 0.85 NPC1 (0.63) ACHEKMT2AGLAHDAC3HDAC4
SCHEMBL2324962 0.85 FAAH (0.49) ACHENPC1RAB9A
SCHEMBL4769744 0.84 KMT2A (0.57) ACHEKMT2AGLAHDAC3HDAC4
SCHEMBL21382248 0.84 KMT2A (0.57) ACHEKMT2AGLAHDAC3HDAC4
SCHEMBL8585756 0.83 KMT2A (0.56) ACHEKMT2AGLAHDAC3HDAC4
SCHEMBL11547458 0.83 ACHE (0.48) ACHEKMT2AGLA
SCHEMBL28219082 0.82 MGLL (0.60) ACHEKMT2AGLAMEN1NPC1
SCHEMBL27887140 0.82 KMT2A (0.55) ACHEKMT2AGLAHDAC3HDAC4
SCHEMBL28364907 0.81 CA1 (0.54) ACHEKMT2AGLAHDAC3HDAC4
SCHEMBL30661069 0.81 KMT2A (0.53) ACHEKMT2AGLAHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6500865-B1 POTENTIATING GLUTAMATE RECEPTORS BY ADMINISTERING N-1-(4-(4-(2-METHANESULFONAMIDO ETHYL)PHENY)PHENYL)ETHYL 2-PROPANE SULFONAMIDE FOR LEARNING ENHANCEMENT AND PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS, PSYCHOSIS OR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY 2002-12-31 US disclosed